Literature DB >> 24001749

Normotensive incidentally discovered pheochromocytomas display specific biochemical, cellular, and molecular characteristics.

Magalie Haissaguerre1, Maïté Courel, Philippe Caron, Sophie Denost, Christophe Dubessy, Philippe Gosse, Vincent Appavoupoulle, Geneviève Belleannée, Marie-Laure Jullié, Maité Montero-Hadjadje, Laurent Yon, Jean-Benoît Corcuff, Cédric Fagour, Catherine Mazerolles, Tristan Wagner, Marie-Laure Nunes, Youssef Anouar, Antoine Tabarin.   

Abstract

CONTEXT: A number of incidentally discovered pheochromocytomas are not associated with hypertension. The characteristics of normotensive incidentally discovered pheochromocytomas (NIPs) are poorly known.
OBJECTIVE: The purpose of this work was to assess the clinical, hormonal, histological, and molecular features of NIPs.
DESIGN: This was a retrospective cohort recruited from 2001 to 2011 in 2 tertiary care medical departments. PATIENTS AND METHODS: Clinical, biological, and radiological investigations performed in 96 consecutive patients with sporadic unilateral pheochromocytomas were examined; 47 patients had overt pheochromocytomas responsible for hypertension. Among the patients with incidental pheochromocytomas, 28 had hypertension and 21 were normotensive (NIPs). A total of 62 tumors were examined to determine the Pheochromocytoma of the Adrenal Gland Scale Score, and 29 were studied for the expression of 16 genes involved in chromaffin cell function.
RESULTS: Tumor size and metaiodobenzylguanidine (MIBG) scintigraphy results were similar for hypertensive pheochromocytomas (HPs) and NIPs. Patients with NIPs displayed reduced summed levels of urinary catecholamines and metanephrines and, more specifically, reduced levels of adrenaline and metadrenaline compared with those of patients with HPs (P < .001). Urinary metanephrines had 98% diagnostic sensitivity in patients with HPs and only 75% in patients with NIPs (P < .01). Tumor diameter positively correlated with the total amount of urinary concentrations of metanephrines in patients with HPs (P < .001) but not in patients with NIPs. NIPs displayed global decreased chromaffin gene expression (reaching significance for 5 of them) and 2 corresponding proteins (phenylethanolamine N-methyltransferase and secretogranin II) and a significant increase in the cellularity, mitotic activity, and presence of atypical mitosis (P < .05).
CONCLUSIONS: NIPs differ from pheochromocytomas responsible for hypertension and display features of altered chromaffin differentiation. These tumors may be misdiagnosed with the use of the usual biological diagnostic tools.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24001749     DOI: 10.1210/jc.2013-1844

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Symptom-dependent cut-offs of urine metanephrines improve diagnostic accuracy for detecting pheochromocytomas in two separate cohorts, compared to symptom-independent cut-offs.

Authors:  Yoon Young Cho; Kee-Ho Song; Young Nam Kim; Seong Hee Ahn; Hyeonmok Kim; Sooyoun Park; Sunghwan Suh; Beom-Jun Kim; Soo-Youn Lee; Sail Chun; Jung-Min Koh; Seung Hun Lee; Jae Hyeon Kim
Journal:  Endocrine       Date:  2016-08-02       Impact factor: 3.633

Review 2.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

3.  Adrenal Incidentaloma Needs thorough Biochemical Evaluation - An Institutional Experience.

Authors:  Akash N Shah; Uma K Saikia; Bipul K Chaudhary; Ashok K Bhuyan
Journal:  Indian J Endocrinol Metab       Date:  2022-04-27

Review 4.  A Guide to Pheochromocytomas and Paragangliomas.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-28

Review 5.  Preoperative Management of Pheochromocytoma and Paraganglioma.

Authors:  Fang Fang; Li Ding; Qing He; Ming Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.